• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Exercise for the Prevention of Anthracycline-induced Functional Disability and Cardiac Dysfunction: The BReast Cancer Randomized EXercise InTervention (BREXIT) Study
Conclusions: In women with early-stage BC undergoing AC, 12-months of ExT did not attenuate functional disability but provided large and clinically meaningful benefits on VO2peak and cardiac reserve. Clinical Trial Registration: URL: https://www.anzctr.org.au/ Unique Identifier: ACTRN12617001408370.PMID:36342348 | DOI:10.1161/CIRCULATIONAHA.122.062814
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Stephen J Foulkes Erin J Howden Mark J Haykowsky Yoland Antill Agus Salim Sophie S Nightingale Sherene Loi Piet Claus Kristel Janssens Amy M Mitchell Leah Wright Ben T Costello Anniina Lindqvist Lauren Burnham Imogen Wallace Robin M Daly Steve F Fraser An Source Type: research

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses
CONCLUSIONS: In people without manifest cardiovascular disease or diabetes, mild-to-moderate kidney dysfunction is causally related to risk of CHD, highlighting the potential value of preventive approaches that preserve and modulate kidney function.PMID:36314129 | DOI:10.1161/CIRCULATIONAHA.122.060700
Source: Circulation - October 31, 2022 Category: Cardiology Authors: Liam Gaziano Luanluan Sun Matthew Arnold Steven Bell Kelly Cho Stephen K Kaptoge Rebecca J Song Stephen Burgess Daniel C Posner Katja Mosconi Cassianne Robinson-Cohen Amy Mason Thomas R Bolton Ran Tao Elias Allara Petra Schubert Lingyan Chen James R Stale Source Type: research

Deep Lipidomics in Human Plasma - Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation
Conclusions: We identified several lipids associated with cardiometabolic disease risk. A subset was beneficially altered by a dietary fat intervention, which supports substitution of dietary saturated FAs with unsaturated FAs as a potential tool for primary disease prevention.PMID:35422138 | DOI:10.1161/CIRCULATIONAHA.121.056805
Source: Circulation - April 15, 2022 Category: Cardiology Authors: Fabian Eichelmann Laury Sellem Clemens Wittenbecher Susanne J äger Olga Kuxhaus Marcela Prada Rafael Cuadrat Kim G Jackson Julie A Lovegrove Matthias B Schulze Source Type: research

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Conclusions: PRONOUNCE is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely due to smaller than planned number of participants and events and no difference in MACE at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02663908.PMID:34459214 | DOI:10.1161/CIRCULATIONAHA.121.056810
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Renato D Lopes Celestia S Higano Susan F Slovin Adam J Nelson Robert Bigelow Per S S ørensen Chiara Melloni Shaun G Goodman Christopher P Evans Jan Nilsson Deepak L Bhatt Noel W Clarke Tine K Olesen Belinda T Doyle-Olsen Henriette Kristensen Lauren Arney Source Type: research

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque.
Conclusions: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk, prior to, during and after treatment, should be considered among patients on an ICI. PMID: 33003973 [PubMed - as supplied by publisher]
Source: Circulation - October 1, 2020 Category: Cardiology Authors: Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG Tags: Circulation Source Type: research

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
CONCLUSIONS: In this population-based study, aromatase inhibitors were associated with increased risks of heart failure and cardiovascular mortality compared with tamoxifen. There were also trends toward increased risks, although nonsignificant, of myocardial infarction and ischemic stroke. The increased risk of cardiovascular events associated with aromatase inhibitors should be balanced with their favorable clinical benefits compared with tamoxifen. PMID: 32065766 [PubMed - in process]
Source: Circulation - February 17, 2020 Category: Cardiology Authors: Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L Tags: Circulation Source Type: research

Pages: 1  2